Skip to main content

Schizophrenia

Center of Excellence

Leaders in the field sharing authoritative insights and institutional best practices.
SCHIZOPHRENIA CENTER OF EXCELLENCE
In this podcast, Schizophrenia Section Editor Leslie Citrome, MD, MPH, reviews recent developments and possible upcoming advances in the treatment of schizophrenia, including new mechanisms of action and methods of delivering medicine.
Q&A
Isabela Pina, MD, discusses her study that found positive psychology interventions may be a beneficial resource for patients on the schizophrenia spectrum, with possible impacts on well-being and symptom reduction.
Q&A
In this Q&A, Katlyn Nemani, MD, of the New York University School of Medicine, discusses her study which found a schizophrenia spectrum diagnosis was associated with increased mortality risk in patients with COVID-19.
Q&A
Researcher Benjamin Perry, MRCPsych, of the University of Cambridge, England, discusses a study published in JAMA Psychiatry which linked physical conditions early in life with later psychiatric disorders.
Q&A
Alice Egerton, PhD, discusses a study which found that symptom improvements in people with treatment-resistant schizophrenia who switch to clozapine may be related to reductions in glutamate in the caudate nucleus.
VIDEO
Kristin Bigos, PhD, of Johns Hopkins Medicine, Baltimore, Maryland, discusses research that could advance the development of treatments focused on cognition in people with schizophrenia or other serious mental illness.
PRESENTATION
A multidisciplinary approach involving a variety of health and medical professionals can help patients with schizophrenia achieve maximum success, Leslie Citrome, MD, MPH, said at a recent Psych Congress Regionals virtual meeting.
YOUR QUESTIONS ANSWERED
Psych Congress Steering Committee member Rakesh Jain, MD, MPH, discusses strategies for treating patients who are still psychotic while taking the maximum dosage of a long-acting injectable medication.
Q&A
Christoph Correll, MD, and Sanjai Rao, MD, respond to questions asked by attendees of a Psych Congress 2020 session they presented on managing weight gain and metabolic disruptions in patients with schizophrenia.
YOUR QUESTIONS ANSWERED
Psych Congress Steering Committee member Rakesh Jain, MD, MPH, discusses the use of long-acting injectables for patients with dementia and paranoia or other delusions.
Back to Top